The webinar will feature a presentation by Key Opinion Leader (KOL) Richard B. Lipton, M.D. (Albert Einstein College of Medicine) who will discuss the current treatment landscape, patient journey, and unmet medical need in treating patients with acute migraine. Dr. Lipton will also discuss ELYXYB as a treatment option for acute migraines. ELYXYB is the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Dr. Lipton and management will be available to answer questions following the formal presentations.

The BioDelivery Sciences International management team will also provide an overview of the migraine market and rationale for the ELYXYB product acquisition, as well as corporate and financial updates.